Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2025)
Historic Net Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 4174.62%.
- Insight Molecular Diagnostics' Net Margin rose 75584300.0% to 4174.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 1383.33%, marking a year-over-year increase of 24833900.0%. This contributed to the annual value of 3245.14% for FY2024, which is 30504600.0% down from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Net Margin is 4174.62%, which was up 75584300.0% from 1880.69% recorded in Q2 2025.
- Insight Molecular Diagnostics' Net Margin's 5-year high stood at 1.65% during Q1 2023, with a 5-year trough of 16497.81% in Q4 2022.
- In the last 5 years, Insight Molecular Diagnostics' Net Margin had a median value of 1873.82% in 2025 and averaged 4003.79%.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Net Margin surged by 616638300bps in 2021, and later plummeted by -154979500bps in 2022.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Net Margin stood at 999.86% in 2021, then tumbled by -1550bps to 16497.81% in 2022, then skyrocketed by 91bps to 1558.74% in 2023, then tumbled by -45bps to 2262.92% in 2024, then tumbled by -84bps to 4174.62% in 2025.
- Its Net Margin stands at 4174.62% for Q3 2025, versus 1880.69% for Q2 2025 and 312.02% for Q1 2025.